Earlier this week, the company's scientific co-founders published an improved version of the ATAC-seq method that allows them to analyze frozen tissue.
The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.
The National Cancer Institute-led team used a CRISPR-based approach to identify genes like APLNR that, when mutated, make cancers resistant to immunotherapy.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
Neon Therapeutics is sponsoring a Phase Ib trial of neoantigen-based vaccines in combination with anti-PD-1 treatment in melanoma, lung cancer, and bladder cancer.
The two companies plan to combine their respective gene editing and neoantigen discover technologies in order to develop new T cell therapies for cancer patients.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.
In 86 pretreated cancer patients with mismatch repair deficiency, researchers saw objective response rates exceeding 50 percent after anti-PD-1 immunotherapy.
In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.
The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.
